References

Neuropathology of Parkinson disease

10.1016/j.parkreldis.2017.07.033 · 2018 · External reference

Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state

10.1093/brain/awab446 · 2022 · External reference

White matter changes in Parkinson’s disease

10.1038/s41531-023-00592-z · 2023 · External reference

Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration

10.1016/s1474-4422(13)70124-8 · 2013 · External reference

Heterogeneity of small vessel disease: A systematic review of MRI and histopathology correlations

10.1136/jnnp.2009.204685 · 2011 · External reference

Cerebral small vessel disease: A review of clinical, radiological, and histopathological phenotypes

10.1111/j.1747-4949.2011.00725.x · 2012 · External reference

Pathogenesis of leukoaraiosis: A review

10.1161/01.str.28.3.652 · 1997 · External reference

What are white matter hyperintensities made of? Relevance to vascular cognitive impairment

10.1161/jaha.114.001140 · 2015 · External reference

Prevalence of cerebrovascular lesions in Parkinson’s disease. A postmortem study

10.1007/s00401-003-0676-3 · 2003 · External reference

Extracranial arterial wall volume is increased and shows relationships with vascular MRI measures in idiopathic Parkinson’s disease

10.1016/j.clineuro.2018.02.013 · 2018 · External reference

Progression of white matter hyperintensities in Alzheimer disease, dementia with Lewy bodies, and Parkinson disease dementia: A comparison with normal aging

10.1097/01.jgp.0000236596.56982.1c · 2006 · External reference

Modifiable vascular risk factors, white matter disease and cognition in early Parkinson’s disease

10.1111/ene.13797 · 2019 · External reference

White matter hyperintensities are linked to future cognitive decline in de novo Parkinson’s disease patients

10.1016/j.nicl.2018.09.025 · 2018 · External reference

Cross-sectional and longitudinal associations between total and regional white matter hyperintensity volume and cognitive and motor function in Parkinson’s disease

10.1016/j.nicl.2019.101870 · 2019 · External reference

Brain atrophy and white matter hyperintensities in early Parkinson’s disease

10.1002/mds.22754 · 2009 · External reference

Age- and disease-related cerebral white matter changes in patients with Parkinson’s disease

10.1016/j.neurobiolaging.2019.05.004 · 2019 · External reference

White matter hyperintensities in patients with Parkinson’s disease: A systematic review and meta-analysis

10.1016/j.jns.2021.117481 · 2021 · External reference

Effects of white matter hyperintensity on cognitive function in PD patients: A meta-analysis

10.3389/fneur.2023.1203311 · 2023 · External reference

The contribution of white matter lesions to Parkinson’s disease motor and gait symptoms: A critical review of the literature

10.1007/s00702-015-1470-9 · 2016 · External reference

Frontal and periventricular brain white matter lesions and cortical deafferentation of cholinergic and other neuromodulatory axonal projections

2009 · External reference

A multicenter longitudinal study of cholinergic subgroups in Parkinson disease

10.1038/s41467-025-60815-0 · 2025 · External reference

Progression of regional cortical cholinergic denervation in Parkinson’s disease

10.1093/braincomms/fcac320 · 2022 · External reference

Cholinergic innervation of the human striatum, globus pallidus, subthalamic nucleus, substantia nigra, and red nucleus

10.1002/cne.903230209 · 1992 · External reference

Unresolved reference

2004 · External reference

Cholinergic systems, attentional-motor integration, and cognitive control in Parkinson’s disease

10.1016/bs.pbr.2022.01.011 · 2022 · External reference

The cholinergic brain in Parkinson’s disease

10.1002/mdc3.13319 · 2021 · External reference

Cholinergic system changes in Parkinson’s disease: Emerging therapeutic approaches

10.1016/s1474-4422(21)00377-x · 2022 · External reference

Cholinergic denervation patterns across cognitive domains in Parkinson’s disease

10.1002/mds.28360 · 2021 · External reference

Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson’s disease

10.1093/brain/awy072 · 2018 · External reference

Cholinergic denervation patterns in Parkinson’s disease associated with cognitive impairment across domains

2025 · External reference

Basal forebrain integrity, cholinergic innervation and cognition in idiopathic Parkinson’s disease

10.1093/brain/awad420 · 2024 · External reference

A new visual rating scale to assess strategic white matter hyperintensities within cholinergic pathways in dementia

10.1161/01.str.0000183615.07936.b6 · 2005 · External reference

Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain

10.1093/brain/121.12.2249 · 1998 · External reference

White matter hyperintensities in cholinergic pathways are associated with dementia severity in e4 carriers but not in non-carriers

10.3389/fneur.2023.1100322 · 2023 · External reference

White matter hyperintensities in cholinergic pathways may predict poorer responsiveness to acetylcholinesterase inhibitor treatment for Alzheimer’s disease

2023 · External reference

Effects of strategic white matter hyperintensities of cholinergic pathways on basal forebrain volume in patients with amyloid-negative neurocognitive disorders

10.1186/s13195-024-01536-2 · 2024 · External reference

Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients

10.1001/archneur.64.2.266 · 2007 · External reference

Differential cholinergic pathway involvement in Alzheimer’s disease and subcortical ischemic vascular dementia

10.3233/jad-122320 · 2013 · External reference

Subcortical white matter hyperintensities within the cholinergic pathways of Parkinson’s disease patients according to cognitive status

10.1136/jnnp-2011-300872 · 2012 · External reference

Subcortical whiter matter hyperintensities within the cholinergic pathways of patients with dementia and parkinsonism

10.1016/j.jns.2015.03.046 · 2015 · External reference

The white matter hyperintensities within the cholinergic pathways and cognitive performance in patients with Parkinson’s disease after bilateral STN DBS

10.1016/j.jns.2020.117121 · 2020 · External reference

Cholinergic changes in Lewy body disease: Implications for presentation, progression and subtypes

10.1093/brain/awae069 · 2024 · External reference

Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases

10.1136/jnnp.55.3.181 · 1992 · External reference

Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines

10.1002/mds.24893 · 2012 · External reference

Regional cerebral cholinergic nerve terminal integrity and cardinal motor features in Parkinson’s disease

10.1093/braincomms/fcab109 · 2021 · External reference

Cerebral topography of vesicular cholinergic transporter changes in neurologically intact adults: A [18F]FEOBV PET study

10.1016/j.nbas.2022.100039 · 2022 · External reference

Highlighting the versatility of the tracerlab synthesis modules. Part 1: Fully automated production of [18F] labelled radiopharmaceuticals using a Tracerlab FXFN

10.1002/jlcr.1865 · 2011 · External reference

In vivo imaging of human cholinergic nerve terminals with (-)-5-18F-fluoroethoxybenzovesamicol: Biodistribution, dosimetry, and tracer kinetic analyses

10.2967/jnumed.113.124792 · 2014 · External reference

A deep learning toolbox for automatic segmentation of subcortical limbic structures from MRI images

10.1016/j.neuroimage.2021.118610 · 2021 · External reference

Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [18F]-FEOBV

10.1038/s41380-018-0130-5 · 2019 · External reference

Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects

10.1038/jcbfm.1992.81 · 1992 · External reference

UBO detector – A cluster-based, fully automated pipeline for extracting white matter hyperintensities

10.1016/j.neuroimage.2018.03.050 · 2018 · External reference

Performance of three freely available methods for extracting white matter hyperintensities: FreeSurfer, UBO detector, and BIANCA

10.1002/hbm.25739 · 2022 · External reference

Unresolved reference

2005 · External reference

Reproducibility of quantitative tractography methods applied to cerebral white matter

10.1016/j.neuroimage.2007.02.049 · 2007 · External reference

Tract probability maps in stereotaxic spaces: Analyses of white matter anatomy and tract-specific quantification

10.1016/j.neuroimage.2007.07.053 · 2008 · External reference

Mediation: R package causal mediation analysis

10.18637/jss.v059.i05 · 2014 · External reference

A robust bootstrap test for mediation analysis

10.1177/1094428121999096 · 2022 · External reference

White matter lesions in Parkinson disease

10.1038/nrneurol.2011.21 · 2011 · External reference

White matter damage in the cholinergic system contributes to cognitive impairment in subcortical vascular cognitive impairment, no dementia

10.3389/fnagi.2017.00047 · 2017 · External reference

Fiber pathways of basal forebrain cholinergic neurons in monkeys

10.1016/0006-8993(87)90783-9 · 1987 · External reference

White matter microstructure in Parkinson’s disease with and without elevated rapid eye movement sleep muscle tone

10.1093/braincomms/fcac027 · 2022 · External reference

Cardiovascular disease and brain health: Focus on white matter hyperintensities

2018 · External reference

Diabetes mellitus and white matter hyperintensity

10.1111/ggi.12666 · 2015 · External reference

Diabetes mellitus exacerbates changes in white matter hyperintensity shapes and volume: A longitudinal study

2025 · External reference

Astrocytes and retrograde degeneration of nigrostriatal dopaminergic neurons in Parkinson’s disease: Removing axonal debris

10.1186/s40035-021-00262-1 · 2021 · External reference

Differential spatial distribution of white matter lesions in Parkinson’s and Alzheimer’s diseases and cognitive sequelae

10.1007/s00702-022-02519-z · 2022 · External reference

Cholinergic centro-cingulate network in Parkinson disease and normal aging

2023 · External reference

Associations between white matter hyperintensities, striatal dopamine loss, and cognition in drug-naïve Parkinson’s disease

10.1016/j.parkreldis.2022.02.020 · 2022 · External reference

Parkinson disease-associated cognitive impairment

10.1038/s41572-021-00280-3 · 2021 · External reference